Eli Lilly and Co
NYSE:LLY
Eli Lilly and Co
NYSE:LLY
Price:
762.7 USD
-1.81%
Updated:
May 2, 2024
Eli Lilly and Co
Cash from Operating Activities
|
Eli Lilly and Co
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
ZTS
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Cash from Operating Activities
$2.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
See Also
What is Eli Lilly and Co's Cash from Operating Activities?
Cash from Operating Activities
4.2B
USD
4.2B
USD
Based on the financial report for Dec 31, 2023, Eli Lilly and Co's Cash from Operating Activities amounts to 4.2B USD.
What is Eli Lilly and Co's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-3%
-3%
Over the last year, the Cash from Operating Activities growth was -40%. The average annual Cash from Operating Activities growth rates for Eli Lilly and Co have been -13% over the past three years , -5% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
